DB
AGIO icon

Dmitry Balyasny’s Agios Pharmaceuticals AGIO Stock Holding History

Dmitry Balyasny’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,009
Closed -$609K – 2965
2026
Q1 		$609K Sell
18,009
-617,060
-97% -$17.5M ﹤0.01% 2275
2025
Q4 		$17.3M Buy
635,069
+139,578
+28% +$4.9M 0.02% 790
2025
Q3 		$19.9M Buy
+495,491
New +$18.6M 0.03% 719
2025
Q1 		– Sell
-248,038
Closed -$8.15M – 2742
2024
Q4 		$8.15M Buy
+248,038
New +$11.7M 0.01% 1049
2024
Q3 		– Sell
-41,793
Closed -$1.8M – 2695
2024
Q2 		$1.8M Sell
41,793
-36,695
-47% -$1.32M ﹤0.01% 1569
2024
Q1 		$2.29M Buy
78,488
+36,485
+87% +$977K ﹤0.01% 1507
2023
Q4 		$935K Sell
42,003
-223,034
-84% -$5M ﹤0.01% 1718
2023
Q3 		$6.56M Buy
265,037
+46,937
+22% +$1.24M 0.01% 1000
2023
Q2 		$6.18M Sell
218,100
-102,907
-32% -$2.56M 0.01% 984
2023
Q1 		$7.37M Buy
321,007
+41,450
+15% +$1.1M 0.02% 911
2022
Q4 		$7.85M Buy
+279,557
New +$7.88M 0.02% 834
2020
Q4 		– Sell
-89,988
Closed -$3.15M – 1277
2020
Q3 		$3.15M Buy
+89,988
New +$3.94M 0.02% 721
2019
Q2 		– Sell
-4,273
Closed -$288K – 1440
2019
Q1 		$288K Sell
4,273
-81,003
-95% -$4.72M ﹤0.01% 1312
2018
Q4 		$3.93M Sell
85,276
-266,721
-76% -$16.5M 0.03% 551
2018
Q3 		$27.1M Sell
351,997
-54,955
-14% -$4.42M 0.12% 233
2018
Q2 		$34.3M Sell
406,952
-276,412
-40% -$24.1M 0.16% 178
2018
Q1 		$55.9M Sell
683,364
-446,899
-40% -$34.5M 0.23% 103
2017
Q4 		$64.6M Buy
1,130,263
+164,111
+17% +$10.3M 0.2% 123
2017
Q3 		$64.5M Buy
966,152
+13,900
+1% +$835K 0.25% 97
2017
Q2 		$49M Buy
952,252
+83,130
+10% +$4.25M 0.2% 130
2017
Q1 		$50.8M Buy
869,122
+184,040
+27% +$8.82M 0.24% 107
2016
Q4 		$28.6M Sell
685,082
-235,622
-26% -$12.4M 0.15% 183
2016
Q3 		$48.6M Buy
920,704
+595,134
+183% +$25.9M 0.28% 115
2016
Q2 		$13.6M Buy
325,570
+227,120
+231% +$11.2M 0.09% 290
2016
Q1 		$4M Buy
98,450
+10,950
+13% +$468K 0.02% 591
2015
Q4 		$5.68M Sell
87,500
-38,661
-31% -$2.54M 0.04% 474
2015
Q3 		$8.91M Buy
+126,161
New +$12.3M 0.07% 375

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dmitry Balyasny's AGIO Position: Q2 2026 in Review

Dmitry Balyasny sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 18,009 shares — an estimated $609K sold.

Dmitry Balyasny first reported a position in AGIO in Q3 2015 and held it in 27 quarters. The position peaked at $64.6M in Q4 2017. 236 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Dmitry Balyasny reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 18,009 Agios Pharmaceuticals shares in Q2 2026, an estimated $609K.
  • Dmitry Balyasny first reported a position in Agios Pharmaceuticals in Q3 2015 and held it in 27 quarters.
  • Dmitry Balyasny's Agios Pharmaceuticals position peaked at $64.6M in Q4 2017.
  • 236 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.